Introduction
CCAAT/enhancer binding protein a (C/EBPa) is a 42 kDa transcription factor. To bind DNA, C/EBPa dimerizes via its leucine zipper domain and then binds DNA via the adjacent basic region . Once bound to DNA, C/EBPa mediates transactivation via its N-terminal transactivation domains Friedman and McKnight, 1990) . C/EBPa contributes to mammalian hepatocyte, adipocyte, and granulocyte differentiation by activating lineage-specific genes (Christy et al., 1989; Friedman et al., 1989; Nuchprayoon et al., 1994; Oelgeschla¨ger et al., 1996) .
In addition, C/EBPa slows G1 to S cell cycle progression and thus cell proliferation via its ability to interact with E2F or cdk2/4 (Umek et al., 1991; Porse et al., 2001; Wang et al., 2001a) , with inhibition of E2F being most critical for cell cycle inhibition in the granulocytic lineage . Repression of E2F-mediated transactivation by C/EBPa depends on the interaction of E2F with the outer, non-DNA contact, surface of C/EBPa's basic region, and the presence of C/EBPa's N-terminal 70 amino acids is also required in fibroblast cell lines (Porse et al., 2001) .
Mice lacking C/EBPa do not develop the granulocytic lineage (Zhang et al., 1997) , dominant inhibition of C/ EBPa in 32Dcl3 cells prevents their neutrophilic differentiation (Wang and Friedman, 2002) , and exogenous C/EBPa is sufficient to direct their terminal differentiation as well as that of U937 cells (Radomska et al., 1998; Wang et al., 1999) . Consistent with the idea that diminished C/EBPa activity contributes to myeloid progenitor transformation via reduction of their differentiation potential, monoallelic point mutations were recently identified in the CEBPA gene in approximately 5% of acute myeloid leukemia (AML) cases (Pabst et al., 2001; Gombart et al., 2002) . These mutations largely fall into two major categories, those that prevent C/EBPa DNA binding via alteration of its C-terminal basic region or leucine zipper domains and those that disrupt translation of the C/EBPa N-terminus, leading to reinitiation of translation at an internal ATG codon. As a result, a 30 kDa C/EBPap30 isoform is expressed. This isoform has the capacity to further reduce C/EBPa activity by inhibiting its transactivation of target genes (Pabst et al., 2001) .
C/EBPap30 and an internally translated isoform of C/ EBPb are also detected in normal cells (Descombes and Schibler, 1991; Calkhoven et al., 2000) . Translational control of C/EBP isoform ratios affects hepatocyte, mammary epithelial, and adipocyte cell development (Diehl et al., 1994; Raught et al., 1995; Calkhoven et al., 2000) .
Herein we investigate the effect of C/EBPap30 on myeloid cell proliferation and differentiation. C/EBPap30 retained the ability to inhibit E2F and G1 to S cell cycle progression in 32Dcl3 myeloid cells, when expressed at high levels, indicating that additional mutations that accelerate G1 progression may be required for transformation of myeloid progenitors in AMLs harboring CEBPA mutations. In addition, while C/EBPap30 inhibited G-CSF receptor expression in 32Dcl3 cells, it did not prevent their terminal maturation in the presence of exogenous G-CSF receptor, a phenotype shared by C/EBPa (À/À) progenitors . Strikingly, the relative affinity of C/ EBPap30 and C/EBPa for C/EBP-binding sites from the NE, GR, and PU.1 genes was variable, with C/ EBPap30 having 5-7-fold reduced affinity for the GR site, threefold reduced affinity for the PU.1 site, and affinity equal to that of C/EBPa for the NE site. Thus, C/EBPap30 may selectively repress the GR and other genes based on differences in binding affinity as well as on differences in their dependence on C/EBPa for expression.
Results

C/EBPap30 inhibits C/EBPa and does not induce granulopoiesis
C/EBPa-ER, the 42 kDa isoform linked to estradiol receptor ligand-binding domain, induces granulocytic differentiation and cell cycle arrest in 32Dcl3 cells (Wang et al., 1999) . 32Dcl3 cells are a diploid, nonleukemic, murine cell line, which requires IL-3 signals to survive and proliferate, undergoes p53 induction and cell cycle arrest in response to DNA damage, and differentiates to neutrophils in response to granulocyte-colony stimulating factor (G-CSF) signals (Valtieri et al., 1987; Britos-Bray et al., 1998) . By deleting residues 1-106 from the cDNA encoding rat C/ EBPa-ER, we enforced translation initiation from methionine 118, leading to expression of C/EBPap30-ER ( Figure 1a) . To assess the transcriptional activities of this fusion protein, 293T cells were transduced with p(C/EBP) 2 TKLUC, a reporter containing two consensus C/EBP-binding sites from the NE gene linked to a minimal thymidine kinase promoter and the luciferase cDNA, and vectors expressing C/EBPa-ER or C/ EBPap30-ER. Duplicate dishes were cultured in the presence or absence of 4-hydroxytamoxifen (4HT), an estradiol analog. C/EBPa-ER activated the reporter 15-fold, on average, whereas C/EBPap30-ER was inactive (Figure 1b, left panel) . 293T cells were then transfected with 30 ng MSV-C/EBPa and increasing amounts of pBabePuro-C/EBPap30-ER, in the absence or presence of 4HT. Approximately twofold reduction in transactivation was achieved at a 3 : 1 or 5 : 1 ratio and a threefold reduction was detected at a 7 : 1 ratio ( Figure 1b, right panel) . For comparison, we also assessed the activity of human C/EBPa and C/EBPap30 in related assays in 293T cells, using 10-fold less expression vector as the CMV promoter is stronger than the LTR in pBabePuro. Relative to the empty CMV vector, hC/EBPa induced the reporter 40-fold and hC/EBPap30 fivefold ( Figure 1c , left panel). Greater acitivity of hC/EBPa versus rat C/EBPap30-ER in this assay may reflect the stronger promoter directing expression of the human isoform. In addition, hC/ EBPap30 inhibited transactivation by hC/EBPa by 3-5-fold ( Figure 1c, right panel) .
32Dcl3 cells were transduced with pBabe-C/EBPap30-ER, and subclones were obtained by limiting We compared the ability of C/EBPa-ER and C/ EBPap30-ER to induce differentiation of 32Dcl3 cells proliferating in IL-3 by assessing their induction of granulocytic markers in estradiol, which is less toxic to these cells than 4HT, by Northern blotting (Figure 2b ). C/EBPa-ER induced the MPO, Lys, and LF mRNAs, whereas C/EBPap30-ER was inactive.
C/EBPap30 inhibits E2F and G1 cell cycle progression
We then compared inhibition of cell cycle progression in 32D-aER and 32D-ap30-ER cells in IL-3, as well as in a previously described control line (Wang and Friedman, 2002) expressing the ER segment alone (Figure 3a) . After exposure to estradiol for 48 h, both aER and ap30-ER-1 cells demonstrated a strong G1 arrest, as well as a G2 arrest, whereas cell cycle progression was not altered in ap30-ER-2 cells. The G1/S ratio was increased 2.5-3-fold in the aER and ap30-ER-1 cells at 48 h (data not shown). Few apoptotic cells with sub-2n DNA content were seen at this time point. Consistent with these findings, 32D-aER and 32D-ap30-ER-1 cells exposed to estradiol proliferated more slowly than untreated cells for 2 days and then died over a 2-day period, whereas ER cell proliferation was unaffected and ap30-ER-2 cell growth was only mildly affected ( Figure 3b ). As C/EBPa inhibits E2F activity in other lineages (Porse et al., 2001) , we compared the activity of pE2F6-TATA-LUC in NIH 3T3 cells and in 32D-aER and 32D-ap30-ER-1 cells (Figure 3c ). 3T3 cells were employed as they demonstrated low basal E2F activity. E2F1/DP-1 activated the reporter approximately 30-fold under the conditions employed (not shown). As observed previously, the N-terminal region of C/EBPa was required for inhibition of exogenous E2F in the fibroblastic 3T3 cell line, whereas both aER and ap30-ER inhibited endogenous E2F activity similarly in 32Dcl3 myeloblasts.
C/EBPap30 inhibits G-CSF receptor expression but not further differentiation
We next sought to determine the effect of C/EBPap30-ER on G-CSF-induced 32Dcl3 differentiation to neutrophils. As inhibition of C/EBP was previously shown to reduce G-CSF receptor (GR) expression (Friedman, 1996; Zhang et al., 1997; Wang and Friedman, 2002) , we examined the expression of GR expression in 32D-ap30-ER-1 cells ( Figure 4a , left panels). Addition of estradiol almost completely eliminated surface GR protein expression. The GR promoter is regulated by C/EBPa (Smith et al., 1996) . Consistent with the idea that the C/EBPap30 reduces GR gene transcription, addition of estradiol reduced GR mRNA expression in 32D-ap30-ER-1 cells, but not in parental 32Dcl3 cells ( Figure 4b ).
To enable assessment of the effect of C/EBPap30 on granulopoiesis independent of its affect on GR expression, we transduced exogenous GR into 32D-ap30-ER-1 cells. High-level expression was evident in 32D-ap30ER/ GR cells, representing pooled transductants, and this was not affected by estradiol ( Figure 4a , right panels). A subclone that retained C/EBPap30-ER and GR expression was cultured in IL-3 in the presence of estradiol and in G-CSF in the absence or presence of estradiol, and cell morphology was visualized by Wright's-Giemsa staining of cell cytospins ( Figure 5a ). Cytoxicity was evident in IL-3, likely due to cell cycle arrest. In G-CSF alone, neutrophilic forms were evident by day 2, and in the presence of both G-CSF and estradiol, both cytoxicity and 2-4-lobed nuclei representing nuclear maturation were evident on days 2 and 3. Total cellular RNAs from ap30ER/GR-1 cells exposed to G-CSF for 1-4 days in the absence or presence of estradiol were then subjected to Northern blotting for MPO, Lys, and C/EBPe (Figure 5b ). Consistent with the evident morphologic differentiation, induction of these granulocytic markers was not prevented by C/EBPap30-ER. In addition, LF mRNA was detected at similar low levels with or without estradiol, NE mRNA was below our level of detection by Northern blotting, and PU.1 mRNA levels actually increased to a greater extent in response to G-CSF in the presence of estradiol (data not shown). Perhaps cell cycle arrest contributes to the more rapid induction of the C/EBPe and PU.1 mRNAs . To facilitate interpretation of these findings, we compared exogenous C/EBPap30-ER levels with endogenous C/EBPa during 32Dcl3 differentiation. Total cellular protein extracts prepared from 32D-ap30ER/GR-1 cells cultured in G-CSF and estradiol for 0, 1, 2, or 3 days were subjected to Western blotting 6 32Dcl3, 32D-C/EBPa-ER (aER), 32D-C/EBPap30-ER-1, and -2 (ap30-ER-1, -2) cells were subjected to Western blotting using ERa antiserum (top) or b-actin antibody (bottom). (b) Total cellular RNAs (10 mg) prepared from 32D-aER and 32D-ap30-ER-1 cells exposed to estradiol (E2) for 0, 1, or 2 days were subjected to Northern blotting sequentially for MPO, Lys, LF, and b-actin Selective C/EBPap30 DNA binding R Cleaves et al using a C/EBPa antiserum ( Figure 5c ). C/EBPap30-ER levels diminished during the first day most likely due to decreased stability when released from heat shock proteins by estradiol, as a similar decrease in levels is seen if estradiol is added in IL-3 (data not shown). The lower panel, showing endogenous C/EBPa expression, is a several-fold longer exposure of the same blot. Thus, C/ EBPap30-ER levels exceed C/EBPa levels by approximately 10-fold and yet do not prevent granulocytic maturation in the presence of exogenous GR.
C/EBPap30 selectively inhibits C/EBPa DNA binding due to variable DNA affinity
Evidence indicating that C/EBPa and C/EBPap30 differ in their affinities for DNA has been presented, and it was suggested that species differences may account for earlier reports demonstrating that rodent C/EBPa and C/EBPap30 bind with equal affinities (Pabst et al., 2001) . To further examine these issues, 293T cells were first transduced with expression vectors for rat C/EBPa-ER and C/EBPap30-ER and with the empty vector. Nuclear extracts were prepared and subjected to Western blotting and gel shift assay (Figure 6a ). C/ EBPa-ER was expressed at a several-fold higher level than C/EBPap30-ER (compare first two lanes of left panel), likely reflecting use of an engineered perfect consensus Kozak sequence for translation initiation in the longer isoform in contrast to the naturally occurring, less than perfect consensus in the shorter isoform. Densitometric analysis indicates that, taking into account their relative expression level, these two C/ EBPs bound the murine NE oligonucleotide with similar affinity (compare first two lanes of each panel). Note , pBabePuro-C/ EBPap30-ER (ap30ER), or pBabePuro (Babe). Duplicate wells were cultured 74HT. Luciferase and b-galactosidase activities were determined from cell extracts 24 h later. %E2F activity is the ratio of activity ( þ ) estradiol to the activity (À) estradiol (mean and s.e. from two determinations). 32D-aER (aER), 32D-ap30-ER-1 (ap30ER), or 32D-ER (ER) cells transfected with 10 mg pE2F6-TK-LUC were split into two cultures 74HT for 48 h in IL-3. The reporter activity ( þ ) estradiol divided by the activity (À) estradiol is shown for each cell line (mean and s.e. from two determinations)
Selective C/EBPap30 DNA binding R Cleaves et al that probe is in excess. We then sought to determine whether rat C/EBPap30-ER would inhibit C/EBPa DNA binding. pBabePuro or pBabePuro-C/EBPap30-ER was transduced with MSV-C/EBPa at a 3 : 3, 3 : 1, or 9 : 1 mg ratio. pBabePuro (pB) itself lowered C/EBPa DNA-binding activity, reflecting promoter competition, with the effect being very apparent at the 9 : 1 ratio (right panel). At a 3 : 3 ratio of input DNA, C/EBPap30-ER was expressed at a higher level than C/EBPa, whereas at a 3 : 1 ratio, their expression was similar (left panel). DNA binding at the higher ratio was not reduced by C/EBPap30-ER, and was even increased, compared to the pBabePuro only gel shift lanes, consistent with the conclusion that C/EBPap30-ER does not prevent interaction of C/EBPa with the C/ EBP site in the NE promoter.
To assess the possibility that hC/EBPap30 may behave differently, we then carried out an analogous assessment of the relative affinity of hC/EBPa and hC/ EBPap30 for the NE oligonucleotide (Figure 6b , left lanes). Again, the p30 isoform was expressed at a lower level, and taking this difference into account densitometric analysis indicated that their affinities for the NE binding site are identical (Figure 6c ). Again probe was maintained in excess, by employing 0.5 mg of extract. Also, again taking into consideration use of less hC/ EBPa in the 3 : 1 compared to the 3 : 3 samples, hC/ EBPap30 did not inhibit binding of hC/EBPa to the NE probe.
As different reports comparing the affinities of C/ EBPa and C/EBPap30 employed different binding sites, we next considered the possibility that the relative affinities of C/EBPa and C/EBPap30 differ between sites. The relative affinities of hC/EBPa and hC/ EBPap30 for two additional sites, derived from the human GR or murine PU.1 promoters, were assessed (Figures 6b and c) . We chose these sites as they, like the C/EBP consensus in the NE promoter, are known to The relative affinities of C/EBPa and C/EBPap30 differ among binding sites but not between species. (a) 293T cells in 100 mM dishes were transiently transfected with 3 mg pBabePuro-C/EBPaER, pBabePuro-C/EBPap30-ER, or pBabePuro (pB) or with pBabePuro or pBabePuro-C/EBPap30-ER and pMSV-C/EBPa (a) at (in mg) 3 : 3, 3 : 1, or 9 : 1 ratios, in the presence of estradiol. After 48 h, nuclear extracts were prepared. A measure of 5 mg of the indicated samples was then subjected to Western blotting using a C/EBPa antiserum (left panel) or gel shift assay using the radiolabelled NE and USF probes (right panels). (b) 293T cells were transfected with 3 mg pCMV-hC/ EBPa, pCMV-hC/EBPap30, or pCMV or with pCMV-hC/EBPap30 and pCMV-hC/EBPa at a 3 : 3 or 3 : 1 ratio. A measure of 5 mg of each extract was subjected to Western blotting (left panel), and 0.2 mg (NE probe), 0.1 mg (GR probe), or 0.5 mg (with PU.1 probe) of each extract was subjected to gel shift assay with NE, GR, PU.1, and USF probes (right panel). (c) The Western and gel shift scans in Figure 7b were subjected to densitometric analysis. Binding of hC/EBPa or hC/ EBPap30 was normalized to protein expression and to USF binding. (d) The 293T extracts employed in (b), containing human C/EBPa (a) or C/EBPap30 (ap30), were subjected to gel shift assay using a range of radiolabelled NE, PU.1, GR (human), or mGR (murine) probe concentrations (0.1-8.0 ng) as indicated. However, the hC/EBPap30 extract was employed at 0.4 mg for the NE, 0.2 mg for the GR and mGR, and 1.0 mg for the PU.1 probes to compensate for its reduced expression Selective C/EBPap30 DNA bindingbe employed with each probe to ensure probe excess. Strikingly, hC/EBPap30 had sevenfold reduced affinity for the GR site, as described previously (Pabst et al., 2001) , and threefold reduced affinity for the PU.1 site. At a 3 : 3 DNA input ratio, affinity for the GR or PU.1 oligonucleotides was only mildly reduced compared to binding with hC/EBPa alone. However, at a 3 : 1 ratio, with C/EBPap30 now in excess, binding by hC/EBPa to the GR and PU.1 oligonucleotides was significantly reduced, in contrast to the results with the NE probe. Of note, when an N-terminal C/EBPa antiserum was added to the 3 : 1 samples, with either the NE, GR, or PU.1 probe, the entire C/EBP complex was supershifted (not shown), indicating that residual binding is not due to hC/EBPap30 homodimers. The greater effect on C/ EBPa binding to the GR site may account for our finding that C/EBPap30 inhibits endogenous GR expression in 32Dcl3 cells but not subsequent maturation in the presence of exogenous GR.
To further confirm our conclusion that C/EBPap30 has reduced affinity for the C/EBP sites in the human GR and murine PU.1 genes but not the murine NE gene, we carried out gel shift analyses using a broad range of probe concentrations. We also assessed the affinities of C/EBPa and C/EBPap30 for the murine GR genomic C/ EBP site (Figure 6d ), as we noted that while the C/EBPbinding sites are identical between the human and murine PU.1 and NE genes, the murine GR site differs from the human site by 1 bp, a C in place of T at position 4 of the 9 bp consensus (Figure 7a) . In this experiment, we attempted to employ equal amounts of each C/EBPa isoform by normalizing input amounts of nuclear extract based on their expression on Western blotting (Figure 6b ). C/EBPa bound the human GR site with approximately threefold increased affinity and the murine GR and PU.1 sites with twofold increased affinity, compared with C/EBPap30, over a range of probe concentrations, whereas C/EBPap30 bound the NE site with 1.5-fold greater affinity. The relative affinities of C/EBPa and C/EBPap30 for the GR, PU.1, and NE sites were thus similar between the studies presented in Figures 6b and d .
Discussion
The key findings of this study are that C/EBPap30, expressed in a subset of AML cases due to point mutations of the CEBPA gene, inhibits GR expression but not subsequent granulopoiesis and that this selective biologic effect may reflect the variable affinity of C/ EBPap30 for C/EBP-binding sites. In leukemias heterozygous for CEBPA mutation, C/EBPa and C/EBPap30 are expressed at similar levels (Pabst et al., 2001) . By 'zippering' with C/EBPa, the p30 isoform would be expected to reduce its affinity for the GR promoter more than the NE and PU.1, the other C/EBP-regulated genes.
Interestingly, C/EBPa(À/À) myeloblasts lack GR expression and yet retain the ability to mature to neutrophils when provided an alternative source of cytokine signalling (Zhang et al., 1997 . Perhaps the GR gene is more sensitive to reduced interaction with C/EBPa than are other C/EBP-regulated genes, including those encoding myeloperoxidase, lysozyme, or lactoferrin (Friedman, 2002a) . The transition from the common myeloid progenitor (CMP) to the granulocytemonocyte progenitor (GMP) requires C/EBPa (Iwasaki-Arai et al., 2002) , and therefore may require expression of the GR. The large majority of the described CEBPA mutations in AML cases reduce expression or DNA-binding activity of the 42 kDa C/ EBPa isoform and so are expected to decrease GR expression in the CMP. Our findings suggest that the subset of CEBPA mutant alleles expressing C/EBPap30 lower GR levels further and so potentiate an arrest in maturation from the CMP to the GMP. C/EBPap30 lacks an N-terminal but retains a central transactivation domain (Friedman and McKnight, 1990) . Three-fold transactivation via a C/EBP cis element by murine C/EBPap30 has been observed (Lin et al., 1993) and we reproduced the finding of mild transactivation by hC/EBPap30 (Pabst et al., 2001) . Perhaps this residual activity accounts for the inability of C/EBPap30 to repress potently the subset of C/EBP target genes for which it retains substantial affinity. In contrast, CHOP, which lacks an intact basic region and so 'zippers' with C/EBP family members and prevents Figure 7 Model for the variable effect of C/EBPap30 on C/EBPa target genes. (a) The C/EBP-binding sites in the NE, human GR, murine GR, and PU.1 promoters, which have variable affinity for C/EBPap30 relative to C/EBPa, are shown. Note that the human and murine NE and PU.1 sites are identical. The C/EBP consensus is also shown. (b) Effect of C/EBPap30 on different C/EBPregulated genes. C/EBPap30 can heterodimerize with C/EBPa (and with other C/EBP family members) and can homodimerize. A subset of target genes, such as the NE or PU.1 genes, will bind each of this dimers with normal or mild to modestly reduced affinity. Once bound, lack of TAD1 from one or both of the dimeric partners may reduce transactivation, although TAD2 may be sufficient in cooperation with other transcription factors for normal expression of some target genes. A second subset of target genes, such as the GR gene, will bind C/EBPp30 hetero-or homodimers poorly, and lack of TAD1 will serve to further reduce expression of these C/EBP-regulated genes Selective C/EBPap30 DNA binding R Cleaves et al their DNA binding, or KRAB-C/EBPa-ER (KaER), which contains a transrepression domain linked to the C/EBPa DNA-binding domain, each markedly reduced endogenous C/EBP activities (Friedman, 1996; Wang and Friedman, 2002) . For 32D-KaER cells, we coexpressed GR and demonstrated that transactivation of both the GR gene and additional C/EBP targets is required for granulocytic maturation, although PU.1 mRNA was elevated by G-CSF signals even in the absence of C/EBP activities (Wang and Friedman, 2002) . Murine C/EBPap30 binds selected DNA targets as well as wild type, when expressed in vitro, in 293T cells, or endogenously in hepatocytes (Lin et al., 1993; An et al., 1996) . The bZIP domains of rat, murine, and human C/EBPa are identical. In contrast, the N-terminal 272 amino acids of rat and murine C/EBPa differ by seven residues, and the same regions of rat and human C/EBPa differ by 22 residues (C Stocking, personal communication). hC/EBPap30 binds the human GR C/EBP-binding site with significantly lower affinity compared with hC/EBPa (Pabst et al., 2001) . We have now provided insight into the apparent species difference in the relative affinity of C/EBPa and C/ EBPap30 for DNA, as the above studies employed different C/EBP-binding sites. When compared quantitatively on the same binding site, the rat and human isoforms behaved similarly, and the GR site has a particularly low affinity for C/EBPap30. Data consistent with reduced affinity of rat C/EBPap30 for the GR compared with the NE promoter were also provided by another group while our work was in progress, although probe excess was not confirmed and relative expression of the two isoforms was not documented in the same cell line (Keeshan et al., 2003) . The sequences of the C/EBPbinding sites in the NE, GR, and PU.1 promoters are compared with each other and with the C/EBP consensus (Figure 7a ). The differences in C/EBPap30 affinity appear to be guided by the third and fourth residues of the consensus, with GG in the NE site allowing the highest affinity, GC in the PU.1 site (one residue a pyrimidine) the next level of affinity, and TT in the GR site (both residues pyrimidine) the lowest affinity. How the presence or absence of residues 1-119 communicates through the protein tertiary structure to affect contact of the bZIP domain with these various residues remains to be determined. Variation in affinity for selected cis elements between alternative bZIP protein isoforms may have broad relevance by providing an additional level of biologic regulation. For example, a truncated form of FosB is expressed due to alternative splicing (Yen et al., 1991) , and use of internal translation start sites may exist among bZIP and other DNAbinding families. In addition, we recently found that C/ EBPa and C/EBPb, which have highly related bZIP domains, bind the NE C/EBP site with similar affinity whereas C/EBPa binds the PU.1 site with much greater affinity . Our findings suggest a model in which the effect of C/EBPap30 on a particular target depends on its affinity for that gene and on whether transactivation mediated by TAD2 is sufficient to allow normal gene expression in conjunction with other transcription factors (Figure 7b ). Interactions with additional regulatory transactivators, such as PU.1, c-Jun, or JunB (Rangatia et al., 2002; Reddy et al., 2002; Liu et al., 2003) , may also differ among C/ EBPa isoforms.
Unlike full-length C/EBPa, C/EBPap30 did not slow the proliferation of 3T3-L1 preadipocytes (Lin et al., 1993) . Consistent with this finding, deletion of 70 Nterminal C/EBPa residues prevented slowing of NIH 3T3 proliferation and repression of E2F activity in a fibroblastic cell line (Porse et al., 2001) . In contrast, we previously found that C/EBPaD1-2-ER, lacking residues 11-70, retained the ability to block 32Dcl3 G1 to S cell cycle progression , and herein we demonstrate that C/EBPap30-ER also slows 32Dcl3 proliferation when expressed at high levels. Inhibition of cell cycle progression in 32Dcl3 cells by C/EBPa depends on the integrity of residues in the outer surface of its basic region which directly contacts E2F family members and is not affected by deletion of the centrally located cdk2/4 interaction domain . Both C/EBPa and C/EBPap30 retain the ability to interact with E2F in myeloid cell extracts (Johansen et al., 2003) . In fibroblasts, the N-terminus of C/EBPa may be required for interaction with a co-repressor that helps mediate inhibition of E2F target genes. Perhaps this protein is lacking in myeloblasts, making it more difficult for C/EBPa to inhibit myeloid cell proliferation. This difference between lineages could help account for the finding that while C/EBPa is expressed only in terminally differentiated, quiescent hepatocytes and adipocytes, it is present at its highest levels in proliferating, immature myeloblasts (Birkenmeier et al., 1989; Friedman et al., 1989; Scott et al., 1992) . On the other hand, immature myeloid cells might also tolerate C/EBPa due to growth inhibitory C/EBPs being expressed as a whole at a relatively low level in myeloblasts compared to later stages of myelopoiesis when C/EBPa, C/EBPb, C/EBPd, and C/EBPe are each expressed. C/EBPd-ER is even more potent than C/ EBPa-ER at slowing Ba/F3 proliferation (W Wang and ADF, unpublished), and CEBPe like C/EBPa interacts with and represses E2F (Theilgaard-Moench et al., 2002) .
In summary, C/EBPap30 reduces expression of a subset of C/EBP target genes, including GR, in part via selective loss in DNA affinity compared with C/EBPa. In this way, C/EBPap30 likely contributes to transformation by inhibiting the maturation of immature myeloid cells. In addition, C/EBPap30 retains the ability to inhibit E2F and slow cell cycle progression, as may a subset of other mutant C/EBPs expressed in AMLs and retaining the basic region (Pabst et al., 2001; Gombart et al., 2002) . However, cell cycle inhibition by C/EBPs requires high-level expression, which may not be relevant in myeloblasts and myeloid progenitors, due to an overall low level of C/EBPs and to the presence of proteins such as AML1 and c-Myb which stimulate proliferation and which are only lost during later stages of maturation (Friedman, 2002b) .
Materials and methods
Cell culture and transduction 32Dcl3 cells were maintained in Iscove's modified Dulbecco's medium (IMDM) with 10% heat-inactivated fetal bovine serum (HI-FBS), 1 ng/ml murine IL-3 (PeproTech, Rocky Hill, NJ, USA) and penicillin-streptomycin (P-S). 32Dcl3 cells were washed twice with phosphate-buffered saline before transfer to IMDM with 10% HI-FBS, 20 ng/ml human G-CSF (Amgen, Thousand Oaks, CA, USA), and P-S. Estradiol was employed at 1 mM and 4-hydroxytamoxifen (4HT) at 200 nM. Ethanol was added at 0.1% to control cultures. The pBabePuro-C/ EBPap30-ER plasmid was generated by deletion of a SmaI fragment encoding residues 1-107 from pBabePuro-C/EBPa-ER (Wang et al., 1999) . This plasmid was packaged using CRE cells and transduced into 32Dcl3 cells as described (Wang et al., 1999) . Subclones resistant to puromycin (2 mg/ml) were obtained by limiting dilution. pLNCX-GR, encoding the human G-CSF receptor, was transduced into one of these clones similarly, followed by selection in G418 (1.2 mg/ml). Surface GR expression was assessed by incubation with biotinylated G-CSF in the presence or absence of excess unlabelled G-CSF followed by exposure to streptavidin-PE and FACS analysis (Wang et al., 2001b) . pCMV-hC/EBPa and pCMV-hC/EBPap30 were kindly provided by D Tenen (Pabst et al., 2001) , and pE2F6-TATA-LUC, pCMV-E2F1, and pCMV-DP1 were kindly provided by B Porse and C Nerlov (Porse et al., 2001) . 32Dcl3 cells were transiently transfected using DEAE-dextran (Suzow and Friedman, 1993) . 293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% HI-FBS, and NIH 3T3 cells were maintained in DMEM with 10% heat-inactivated calf serum. 293T and 3T3 cells were transiently transfected in six-well dishes using 6 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). CMV-bGal was included in transfections where indicated as an internal control.
Cell cycle analysis
Cell accumulation was assessed by enumerating viable cells that exclude Trypan blue dye. Cell cycle analysis was carried out after culture for 48 h in estradiol by staining permeabilized cells with propidium iodide (PI) (Lou et al., 2000) .
Western, Northern, and gel shift assays Western blotting was carried out using antisera specific for ERa (HC-20), C/EBPa (14AA) (Santa Cruz Biotech., Santa Cruz, CA, USA) or b-actin (AC-15) (Sigma, St Louis, MO, USA) as described (Wang et al., 1999) . Total cellular RNAs prepared using RNeasy (Qiagen, Valencia, CA, USA) were subjected to Northern blotting as described (Wang et al., 1999) . Nuclear extracts were employed in a gel shift assay using C/EBP-binding sites from the murine neutrophil elastase (NE), human or murine G-CSF receptor (GR, mGR), or murine PU.1 promoters, and using a USF-binding site as a loading control (Oelgeschla¨ger et al., 1996; Smith et al., 1996; Kummalue and Friedman, 2003 The C/EBP sites are underlined. Each oligonucleotide and its complement includes an identical 4 bp overhang to enable Klenow labelling. C/EBPa antiserum N-19 was employed for supershift assay (Santa Cruz Biotech.).
